Flu Bu ATG - Slavin: Difference between revisions
From OncoWiki
Jump to navigationJump to search
(Created page with "*Fludarabine (Fludara) 30 mg/m<sup>2</sup> IV once per day on days -10 to -5 (6 consecutive days) *Busulfan (Myleran) 4 mg/kg/day PO on days -6 to -5 (2 consecutive da...") |
No edit summary |
||
| Line 2: | Line 2: | ||
*[[Busulfan (Myleran)]] 4 mg/kg/day PO on days -6 to -5 (2 consecutive days) or IV Busulfex 3.2 mg/kg days -6 to -5 | *[[Busulfan (Myleran)]] 4 mg/kg/day PO on days -6 to -5 (2 consecutive days) or IV Busulfex 3.2 mg/kg days -6 to -5 | ||
*[[Antithymocyte globulin (ATG)|ATG-Fresenius]] 10 mg/kg/day on days -4 to -1 (4 consecutive days) | *[[Antithymocyte globulin (ATG)|ATG-Fresenius]] 10 mg/kg/day on days -4 to -1 (4 consecutive days) | ||
==References== | |||
# Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756-63. [http://www.bloodjournal.org/content/91/3/756.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/9446633 PubMed] | |||
Latest revision as of 02:03, 21 September 2016
- Fludarabine (Fludara) 30 mg/m2 IV once per day on days -10 to -5 (6 consecutive days)
- Busulfan (Myleran) 4 mg/kg/day PO on days -6 to -5 (2 consecutive days) or IV Busulfex 3.2 mg/kg days -6 to -5
- ATG-Fresenius 10 mg/kg/day on days -4 to -1 (4 consecutive days)
References
- Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756-63. link to original article contains verified protocol PubMed
